Cargando…

Immunogenicity Risk Assessment for Multi-specific Therapeutics

The objective of this manuscript is to provide the reader with a hypothetical case study to present an immunogenicity risk assessment for a multi-specific therapeutic as part of Investigational New Drug (IND) application. In order to provide context for the bioanalytical strategies used to support t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kroenke, Mark A., Milton, Mark N., Kumar, Seema, Bame, Eris, White, Joleen T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571146/ https://www.ncbi.nlm.nih.gov/pubmed/34741215 http://dx.doi.org/10.1208/s12248-021-00642-5

Ejemplares similares

Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
por: Zhou, Yanchen, et al.
Publicado: (2022)

Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays
por: Ducret, Axel, et al.
Publicado: (2021)

Immunogenicity Risk Assessment of Spontaneously Occurring Therapeutic Monoclonal Antibody Aggregates
por: Swanson, Michael D., et al.
Publicado: (2022)

Assessing the Immunogenicity of Biopharmaceuticals
por: Pineda, Carlos, et al.
Publicado: (2016)

Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
por: Davda, Jasmine, et al.
Publicado: (2019)

Looking into the world’s largest elephant population in search of ligninolytic microorganisms for biorefineries: a mini-review
por: Rammala, Bame, et al.
Publicado: (2022)

Immunogenicity of therapeutic proteins: Influence of aggregation
por: Ratanji, Kirsty D., et al.
Publicado: (2014)

A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties
por: Nyborg, Andrew C., et al.
Publicado: (2016)

Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications
por: Carr, Warner W., et al.
Publicado: (2021)

Immunogenicity of Therapeutic Proteins: The Use of Animal Models
por: Brinks, Vera, et al.
Publicado: (2011)

Immunogenic cell death in cancer: concept and therapeutic implications
por: Galluzzi, Lorenzo, et al.
Publicado: (2023)

Recent Advances in Assessing Immunogenicity of Therapeutic Proteins: Impact on Biotherapeutic Development
por: Lu, Yanmei, et al.
Publicado: (2016)

Immunogenic Targets for Specific Immunotherapy in Multiple Myeloma
por: Zhang, Lu, et al.
Publicado: (2012)

Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins
por: Jarvi, Nicole L., et al.
Publicado: (2021)

Site-Specific PEGylation of Therapeutic Proteins
por: Dozier, Jonathan K., et al.
Publicado: (2015)

Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation
por: Khan, Aalia N., et al.
Publicado: (2022)

Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics
por: Joubert, Marisa K., et al.
Publicado: (2016)

Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity
por: Longbrake, Erin E, et al.
Publicado: (2020)

The Therapeutic Value of Monoclonal Antibodies Directed Against Immunogenic Tumor Glycoproteins
por: Arlen, Myron, et al.
Publicado: (2010)

Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicity
por: van Schie, Karin A, et al.
Publicado: (2015)

Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins
por: Smith, Alison, et al.
Publicado: (2016)

Assessing MAPPs assay as a tool to predict the immunogenicity potential of protein therapeutics
por: Di Ianni, Andrea, et al.
Publicado: (2023)

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review
por: Krieckaert, Charlotte Louise Maria, et al.
Publicado: (2010)

Systemically Administered, Target-Specific, Multi-Functional Therapeutic Recombinant Proteins in Regenerative Medicine
por: Järvinen, Tero A.H., et al.
Publicado: (2020)

Three Innovations of Next-Generation Antibiotics: Evolvability, Specificity, and Non-Immunogenicity
por: Shim, Hyunjin
Publicado: (2023)

Editorial: Immunogenicity of Proteins Used as Therapeutics
por: Sauna, Zuben E., et al.
Publicado: (2020)

Preexisting Antibodies to an F(ab′)(2) Antibody Therapeutic and Novel Method for Immunogenicity Assessment
por: Ruppel, Jane, et al.
Publicado: (2016)

Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
por: Tang, Weifeng, et al.
Publicado: (2023)

The Next Generation of Risk Assessment Multi-Year Study—Highlights of Findings, Applications to Risk Assessment, and Future Directions
por: Cote, Ila, et al.
Publicado: (2016)

Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
por: Decraene, Brecht, et al.
Publicado: (2022)

Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics
por: Lee, Yeji, et al.
Publicado: (2023)

Harnessing the non-specific immunogenic effects of available vaccines to combat COVID-19
por: Mosaddeghi, Pouria, et al.
Publicado: (2020)

Measuring the impact of COVID-19 social distancing measures on sexual health behaviours and access to HIV and sexual and reproductive health services for people living with HIV in Botswana
por: Ensor, Samuel, et al.
Publicado: (2023)

Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy
por: Varin, Juliette, et al.
Publicado: (2021)

Design of an observational multi-country cohort study to assess immunogenicity of multiple vaccine platforms (InVITE)
por: Sereti, Irini, et al.
Publicado: (2022)

A Systematic Review of Expression and Immunogenicity of Human Endogenous Retroviral Proteins in Cancer and Discussion of Therapeutic Approaches
por: Müller, Mikkel Dons, et al.
Publicado: (2022)

Mechanisms of immunogenicity in colorectal cancer
por: Sillo, T O, et al.
Publicado: (2019)

Therapeutic uses of antioxidant liposomes
por: Stone, William L., et al.
Publicado: (2004)

Immunogenicity Risk Profile of Nanobodies
por: Ackaert, Chloé, et al.
Publicado: (2021)

Therapeutic Implications of Immunogenic Cell Death in Human Cancer
por: Palombo, Fabio, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5aosht7cov64opotmutbu8fgj8